BR112015000447A2 - derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer - Google Patents

derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer

Info

Publication number
BR112015000447A2
BR112015000447A2 BR112015000447A BR112015000447A BR112015000447A2 BR 112015000447 A2 BR112015000447 A2 BR 112015000447A2 BR 112015000447 A BR112015000447 A BR 112015000447A BR 112015000447 A BR112015000447 A BR 112015000447A BR 112015000447 A2 BR112015000447 A2 BR 112015000447A2
Authority
BR
Brazil
Prior art keywords
thiazol
imidazo
alzheimer
disease
diagnostic agents
Prior art date
Application number
BR112015000447A
Other languages
English (en)
Inventor
Koblet Andreas
Knust Henner
Gobbi Luca
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015000447A2 publication Critical patent/BR112015000447A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo patente de invenção: "derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer". a presente invenção refere-se a derivados de imidazo[2,1-b]tiazol-3-ona de fórmula i em que as variáveis são como definidas nas reivindicações. foi mostrado que os presentes compostos podem ser usados para ligação e imagiologia de agregados de tau e agregados de ß folha relacionados incluindo, além disso, outros agregados de beta-amiloide ou agregados de alfa-sinucleína, especialmente para uso em ligação e imagiologia de agregados de tau em pacientes com alzheimer.
BR112015000447A 2012-08-14 2013-08-06 derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer BR112015000447A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12180367 2012-08-14
PCT/EP2013/066447 WO2014026881A1 (en) 2012-08-14 2013-08-06 Imidazo[2,1]thiazol-3-one derivatives useful as diagnostic agents for alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112015000447A2 true BR112015000447A2 (pt) 2017-06-27

Family

ID=46851292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000447A BR112015000447A2 (pt) 2012-08-14 2013-08-06 derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer

Country Status (12)

Country Link
US (1) US20150157739A1 (pt)
EP (1) EP2885306B1 (pt)
JP (1) JP6228980B2 (pt)
KR (1) KR20150042787A (pt)
CN (1) CN104411709B (pt)
BR (1) BR112015000447A2 (pt)
CA (1) CA2876459A1 (pt)
ES (1) ES2587745T3 (pt)
HK (1) HK1206343A1 (pt)
MX (1) MX2015001546A (pt)
RU (1) RU2015106437A (pt)
WO (1) WO2014026881A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105560831A (zh) * 2016-01-08 2016-05-11 肖鉴 一种治疗不孕不育的中药组合物
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
JP7197476B2 (ja) 2016-07-22 2022-12-27 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
CN110506045B (zh) * 2017-04-12 2023-01-13 帝斯曼知识产权资产管理有限公司 制备咪唑并噻唑酮化合物的方法
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100119599A1 (en) * 2006-12-08 2010-05-13 Archer Pharmaceuticals, Inc. Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
CA2737028C (en) * 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands for aggregated tau molecules
EP2411057B1 (en) * 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
WO2012078909A1 (en) * 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Thiazolpyrimidine proteostasis regulators

Also Published As

Publication number Publication date
RU2015106437A (ru) 2016-10-10
EP2885306B1 (en) 2016-06-01
MX2015001546A (es) 2015-05-11
CN104411709B (zh) 2016-08-24
CA2876459A1 (en) 2014-02-20
US20150157739A1 (en) 2015-06-11
HK1206343A1 (zh) 2016-01-08
JP2015524830A (ja) 2015-08-27
WO2014026881A1 (en) 2014-02-20
CN104411709A (zh) 2015-03-11
ES2587745T3 (es) 2016-10-26
KR20150042787A (ko) 2015-04-21
EP2885306A1 (en) 2015-06-24
JP6228980B2 (ja) 2017-11-08

Similar Documents

Publication Publication Date Title
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015000447A2 (pt) derivados de imidazo[2,1]tiazol-3-ona úteis como agentes de diagnóstico para doença de alzheimer
BR112015008487A2 (pt) compostos de benzeno substituído
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
BR112014030678A2 (pt) formas cristalinas de um modulador de receptor de androgênio
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BR112015003592A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
BR112014026703A2 (pt) inibidores de dna-pk
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112014022214A2 (pt) fenólicos antibacterianos
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112015008447A2 (pt) métodos para tratar câncer
EA201071320A1 (ru) Активаторы глюкокиназы
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112015018504A2 (pt) moduladores de flap
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.